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Abstract
Currently, treatments for ischemic stroke focus on restoring or improving perfusion to the
ischemic area using thrombolytics. The increased hospitalization costs related to thrombolysis are
offset by a decrease in rehabilitation costs, for a net cost savings to the healthcare system.
However, early treatment is essential. The benefit of thrombolysis is time-dependent but only a
very small proportion of patients, 2%, are presently being treated with tPA. In the United States, if
the proportion of all ischemic stroke patients that receive tPA were increased to 4, 6, 8, 10, 15, or
20%, the realized cost saving would be approximately $ 15, 22, 30, 37, 55, and 74 million,
respectively. Being so, efforts should be made to educate the public and paramedics regarding early
stroke signs. Furthermore, additional acute stroke therapy training programs need to be
established for emergency departments. Finally, hospital systems need to be re-engineered to treat
patients as quickly as possible in order to optimize thrombolytic benefit as well as maximize cost-
effectiveness.
Commentary
The global burden of stroke is immense [1,2] and, in fact,
stroke is a major disease in both medical and economic
terms. It is the leading cause of serious, long-term disabil-
ity and the third leading cause of death in the USA [3]. The
prevailing emphasis on cost containment and managed
care has led to increased interest in the economic aspects
of stroke. Even though stroke is a highly prevalent disease,
effective treatment is still limited.
Currently, treatments for ischemic stroke focus on restor-
ing or improving perfusion to the ischaemic area. The cur-
rent treatment for most patients with acute ischaemic
stroke is limited to the management of the symptoms,
antiplatelet therapy, secondary stroke prevention and
rehabilitation [4]. On 18 June 1996, the US Food and
Drug Administration approved the intravenous tissue
plasminogen activator (tPA) as a therapy for acute
ischemic stroke within 3 hours from onset. Shortly there-
after, there was speculation that the acute costs of throm-
bolysis could be offset by the greater likelihood of a
favourable recovery [5]. This estimation was subsequently
confirmed when Markov modelling was used to demon-
strate that the increased hospitalization costs were offset
by a decrease in rehabilitation costs giving a net cost sav-
ings to the healthcare system [6]. It was readily observed
that integrated healthcare systems (acute care, rehabilita-
tion, and nursing home facilities) have an economic
incentive to use tPA in stroke patients [7]. Other authors
have supported the use of tPA as a strategy for reducing
stroke costs, recognizing it as a treatment associated with
important health gains (four to six quality-adjusted life-
years gained per 100 patients over a lifetime) and cost sav-
ings [8-10].
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Unfortunately, the enthusiasm of the late 1990s was
dampened in the early 2000s with the recognition that
only a very small proportion (2%) of stroke patients were
actually being treated with tPA [8]. Over the past 10 years,
the overall proportion of ischaemic stroke patients treated
with tPA has slowly crept up and several urban and non-
urban primary stroke centres report impressive propor-
tions (10% to 20%) of stroke patients receiving tPA espe-
cially in the USA and Canada [11,12]. These findings
confirm that, under ideal circumstances, a higher propor-
tion of patients can have access to this acute therapy. Bar-
riers to more uniform and timely access to stroke centre
care and tPA continue to exist but they are being identified
and addressed.
In the USA, if the proportion of all ischaemic stroke
patients that receive tPA were increased to 4%, 6%, 8%,
10%, 15% or 20%, the realized cost savings would be
approximately US$15, US$22, US$30, US$37, US$55 and
US$74 million, respectively [13]. In Canada, the current
average national tPA utilization is 1.4%. For every increase
of 2 percentage points in utilization, Canadian $ 757,204
could possibly be saved annually (95% confidence inter-
val, maximum loss of Canadian $ 3,823,992 to a maxi-
mum savings of Canadian $ 2,201,252). With a 20% rate,
Canadian > $ 7.5 million could be saved national-wide
during the first year [12].
However, time is crucial. In fact, treating within 3 hours of
the onset of stroke symptoms is a difficult criterion to
meet because the median time from stroke onset to arrival
in an emergency department is between 3 and 6 hours
[14]. As a result, a substantial number of ischaemic stroke
patients are not eligible for intravenous tPA.
In the ECASS III trial, 800 patients received either the tPA
or a placebo between 3 and 4.5 hours after the onset of
symptoms. It was reported that significantly more patients
had a beneficial outcome with tPA than without it [15].
However, the benefit of thrombolysis is time-dependent.
In fact, tPA is nearly twice as efficacious when adminis-
tered within the first 1.5 hours after the onset of a stroke
compared to after 1.5 to 3 hours (odds ratio for the global
outcome, 2.81 for an interval of 0 to 90 minutes, 1.55 for
91 to 180 minutes and 1.40 for 181 to 270 minutes) [16].
In comparison, in ECASS III, the odds ratio was 1.34 for
an interval of 181 to 270 minutes. For one patient to have
a favourable outcome (a score of 0 or 1 on the modified
Rankin scale), the number needed to treat is 14 with the
extended time window. This benefit is clinically meaning-
ful and thus extends the treatment window for patients
who do not arrive at the hospital early. It does not mean,
however, that patients who can be treated within 3 hours
should have their treatment delayed. The 'door-to-needle'
time remains paramount and must be kept as short as pos-
sible in order to increase the chance of a positive outcome.
Thus, all effort should be made to educate the public and
paramedics about the early signs of stroke. Furthermore,
additional acute stroke therapy training programmes need
to be established for emergency departments. Addition-
ally, hospital systems need to be re-engineered to treat
patients as quickly as possible in order to optimize the
thrombolytic benefit as well as to maximize the cost-effec-
tiveness [17,18]. Finally, commitments need to be made
to reduce the time between the onset of stroke and hospi-
tal arrival in order to be able to treat more patients with
tPA. In order to achieve this, even the use of telemedicine
and helicopter transport may be seen to cost-effective
[19,20].
Several studies have suggested that magnetic resonance
imaging (MRI) protocols using diffusion-weighted imag-
ing (DWI) and perfusion-weighted imaging (PWI) before
tPA can identify which patients may benefit from tPA
within and beyond 3 hours after the onset of stroke symp-
toms [21,22]. Despite the increase in imaging costs and
the delay in treating patients because of the increased time
needed to perform MRI, penumbral-based MRI selection
has shown to decrease mortality and improve functional
outcome. A slight increase in total costs over a patient's
lifetime due to the penumbral-based MRI selection can
prove to be highly cost-effective compared to standard
computed tomography-based (CT) care. In fact, the addi-
tion of penumbral-base MRI selection has been shown to
increase the total cost by US$103 over the patient's
remaining lifetime. However, penumbral-based MRI
selection resulted in favourable outcomes more often
than CT-based selection (36.66% versus 35.06%) with an
incremental cost per life year of US$ 1,840 [23]. ECASS III
is correct in suggesting that treatment with tPA is still
effective in patients who present 3 - 4.5 hours after the
onset of stroke symptoms. Furthermore, penumbral-
based MRI selection of patients beyond 3 hours from
onset may improve clinical outcomes. However, it must
be stressed that the sooner patients arrive at hospital for
tPA, the greater the health benefit and cost-effectiveness.
In conclusion, treatment with tPA is beneficial in clinical
trials, effective in the real world and results in a net cost
savings but only a small proportion of stroke patients are
actually being treated with tPA. Research on the barriers
limiting tPA use, strategies to mitigate these barriers and
the experiences of advanced stroke centres suggest that
increasing the use of tPA is possible. If even with small
increases in the proportion of all ischaemic stroke patients
who received tPA were achieved, there could an enormous
savings for healthcare systems.
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